Kwality Pharmaceuticals has secured approval from the Review Committee on Genetic Manipulation (RCGM) to commence pre-clinical toxicity studies for its recombinant Erythropoietin product, 10,000 1U/mL, developed in its Biologics Unit. Erythropoietin is a critical therapeutic used to treat anemia associated with chronic kidney disease (CKD).
This milestone marks a significant step forward in its commitment to expanding its biologics portfolio and addressing critical healthcare needs. With this approval, the company is on track to complete the pre-clinical studies and is diligently preparing for the commercialization of the product in the next fiscal.
Kwality Pharmaceuticals (formerly Kwality Pharmaceuticals) is a pharmaceutical formation company.
